Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α

被引：13

作者：

Hirohama, Daigoro ^{[1
]}

Hoshino, Junichi ^{[1
]}

Hasegawa, Eiko ^{[1
]}

Yamanouchi, Masayuki ^{[1
]}

Hayami, Noriko ^{[1
]}

Suwabe, Tatsuya ^{[1
]}

Sawa, Naoki ^{[1
]}

Takemoto, Fumi ^{[1
]}

Ubara, Yoshifumi ^{[1
]}

Hara, Shigeko ^{[2
]}

Ohashi, Kenichi ^{[3
]}

Takaichi, Kenmei ^{[1
]}

机构：

[1] Toranomon Gen Hosp, Kidney Ctr, Minato Ward, Tokyo 1058470, Japan

[2] Toranomon Gen Hosp, Hlth Management Ctr, Tokyo 1058470, Japan

[3] Toranomon Gen Hosp, Dept Pathol, Tokyo 1058470, Japan

来源：

MODERN RHEUMATOLOGY | 2010年 / 20卷 / 06期

关键词：

TNF-alpha inhibitors; Infliximab; ANCA-associated systemic vasculitis; MPO-ANCA; Necrotizing crescentic glomerulonephritis; RHEUMATOID-ARTHRITIS; WEGENERS-GRANULOMATOSIS; SYSTEMIC VASCULITIS; THERAPY; EFFICACY; ETANERCEPT; INFLIXIMAB; BLOCKADE; SAFETY; TRIAL;

D O I：

10.1007/s10165-010-0339-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report on a 33-year-old woman who presented with positive myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) during rheumatoid arthritis treatment with infliximab. She had a history of worsening arthralgia, and urinalysis showed the new occurrence of hematuria and proteinuria. Renal biopsy showed necrotizing crescentic glomerulonephritis. Immunosuppressive therapy and discontinuation of the infliximab therapy alleviated her arthralgia and improved the urinalysis results. We report this rare case in which an anti-tumor necrosis factor-alpha (TNF-alpha) agent for ANCA-associated systemic vasculitis was studied.

引用

页码：602 / 605

页数：4

共 23 条

[1] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[2] C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab [J].

Ashok, Dayavathi ;

Dubey, Shirish ;

Tomlinson, Ian .

CLINICAL RHEUMATOLOGY, 2008, 27 (02) :261-264

[3] Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides:: an open pilot study on 10 patients [J].

Bartolucci, P ;

Ramanoelina, J ;

Cohen, P ;

Mahr, A ;

Godmer, P ;

Le Hello, C ;

Guillevin, L .

RHEUMATOLOGY, 2002, 41 (10) :1126-1132

[4] Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study [J].

Booth, AD ;

Almond, MK ;

Burns, A ;

Ellis, P ;

Gaskin, G ;

Neild, GH ;

Plaisance, M ;

Pusey, CD ;

Jayne, DRW .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :776-784

[5] Safety and efficacy of TNFα blockade in relapsing vasculitis [J].

Booth, AD ;

Jefferson, HJ ;

Ayliffe, W ;

Andrews, PA ;

Jayne, DR .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (06) :559-559

[6]

Doulton TWR, 2004, CLIN NEPHROL, V62, P234

[7]

Furst DE, 2003, J RHEUMATOL, V30, P2563

[8]

Guillevin L, 2004, J RHEUMATOL, V31, P1885

[9] Differentiating the efficacy of the tumor necrosis factor inhibitors [J].

Haraoui, B .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) :7-11

[10]

Hoffman GS, 1998, ARTHRITIS RHEUM-US, V41, P1521, DOI 10.1002/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO

← 1 2 3 →